While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported its earnings for the fourth ...

Achieving a digital transition that strengthens Europe's strategic competitiveness means addressing the persistent challenges in innovation, adoption, and technological dependency.